The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
暂无分享,去创建一个
Shan Zeng | Cem Akin | Sasa Dimitrijevic | Gerald McMahon | G. Mcmahon | B. Longley | S. Dimitrijević | D. Metcalfe | J. Butterfield | C. Akin | S. Zeng | Dean D Metcalfe | Yongsheng Ma | Joseph H Butterfield | B Jack Longley | Yongsheng Ma | B. Longley
[1] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] Y. Matsuzawa,et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. , 1994, Blood.
[3] G. Mcmahon,et al. New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors. , 2000, Hematology/oncology clinics of North America.
[4] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[5] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[6] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[7] L. Ashman,et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.
[8] Y. Ma,et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. , 1999, The Journal of investigative dermatology.
[9] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[10] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[11] G. Mcmahon,et al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. , 2000, The Journal of investigative dermatology.
[12] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[13] B. Longley,et al. A proposed classification of mastocytosis incorporating molecular genetics. , 2000, Hematology/oncology clinics of North America.
[14] L. Regan,et al. Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.
[15] K. Zsebo,et al. Primary structure and functional expression of rat and human stem cell factor DNAs , 1990, Cell.
[16] G. Dewald,et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.
[17] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] Laura H. Tang,et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.
[19] S. Galli,et al. The kit ligand, stem cell factor. , 1994, Advances in immunology.
[20] Y. Matsuzawa,et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation , 1994 .